- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02949947
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
The goal of this clinical research study is to compare Injectafer® (ferric carboxymaltose) with an iron supplement to learn which may be more effective in improving red blood cell counts in patients who have iron-deficiency anemia (a low red blood cell count) because of a gastrointestinal stromal tumor (GIST) and/or systemic therapy.
The safety of ferric carboxymaltose will also be studied.
This is an investigational study. Ferric carboxymaltose is FDA approved and commercially available to treat iron deficiency anemia; however, it is considered investigational to use in patients who have cancer-related or systemic therapy-related anemia.
Up to 50 participants will take part in this study. All will be enrolled at MD Anderson.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Groups and Study Drug Administration:
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This is done because no one knows if one group is better, the same, or worse than the other.
- If you are in Group A, you will receive ferric carboxymaltose injection by vein over about 15 minutes. You will receive 2 injections about 7 days apart (for example, on Days 0 [the day you are assigned to a study group] and 7).
- If you are in Group B, you will take iron supplements by mouth every day. This is considered standard of care for iron deficiency anemia and the study staff will discuss with you which iron supplements you will take and their risks.
You and the study staff will know to which group you are assigned.
Length of Study:
You may receive up to 2 injections of ferric carboxymaltose (if you are in Group A) or up to 3 months of oral iron supplements (if you are in Group B). You will no longer be able to take the study drug if intolerable side effects occur or if you are unable to follow study directions.
Your participation on the study will be over after you have completed the Week 24 visit.
Study Visits:
Baseline (within 1 week after you have been assigned to a study group):
- You will have a physical exam.
- You will complete a questionnaire about your health. It should take about 5 minutes to complete.
- Blood (about 1 tablespoon) will be drawn for routine tests and to test the level of iron in your blood.
One (1) time every week during Months 1-3, blood (about 1 tablespoon) will be drawn for routine tests.
At about Weeks 4, 8, 12, and 24 (the end-of-study visit):
- You will have a physical exam (Weeks 12 and 24 only).
- You will complete the same questionnaire you did at baseline.
- Blood (about 1 tablespoon) will be drawn for routine tests and to test the level of iron in your blood.
During Weeks 16 and 20, blood (less than 1 tablespoon) will be drawn to test the level of iron in your blood.
If you leave the study before Week 24, you will have the Week 24 study visits as soon as possible after you leave the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- GIST patients with IDA planned to start or are receiving systemic therapy with TKIs.
- Evidence of iron deficiency anemia including, Hgb < 11 g/dL, but > 8 g/dL; and transferrin saturation (TSAT) < 20%.
- No H/O allergic reaction to iron therapy.
- No clinical signs active of bleeding.
- Adequate hematologic (ANC > 1500/mm^3, platelet count > 100,000/mm^3), renal (serum creatinine < 1.5mg/dL), and hepatic (serum bilirubin count < 1.5 x normal and serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 3 x normal) functions.
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.
- Signed informed consent to the study.
- Male and Females of child bearing potential must use acceptable methods of birth control which include oral contraceptives, spermicide with either a condom, diaphragm or cervical cap, use of an intrauterine device (IUD) or abstinence.
- Patients are required to read and understand English to comply with protocol requirements.
- Age >=18 years old.
- Life expectancy of at least 6 months.
Exclusion Criteria:
- Pregnant or lactating women.
- Patients with any co-morbid condition which renders patients at high risk of treatment complication.
- Patient has uncontrolled angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < 40%), uncontrolled cardiac arrhythmia or hypertension, or acute myocardial infarction within 3 months.
- Patient has an active seizure disorder. (Patients with a previous history of seizure disorders will be eligible for the study, if they have had no evidence of seizure activity, and they have been free of antiseizure medication for the previous 5 years).
- Psychological, social, familial, or geographical reasons that would prevent scheduled visits and follow-up.
- Prior surgery or radiotherapy (RT) within 2 weeks of study entry.
- Known hypersensitivity reaction to any component of ferric carboxymaltose.
- Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, or erythropoiesis-stimulating agents), or transfusion of PRBCs in 2 weeks.
- Hemochromatosis or other iron storage disorders.
- Known positive hepatitis with evidence of active disease.
- Patients with overt bleeding.
- Ferritin >/= 800 ng/mL.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A - Ferric Carboxymaltose
Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later. Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24. |
15 mg/kg by vein (up to 750 mg) over 15 min infusion.
Dose repeated 1 week later.
Other Names:
Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
Other Names:
|
Active Comparator: Group B - Iron Supplement
Participants take iron supplements by mouth every day for up to 3 months. Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24. |
Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
Other Names:
Participants take iron supplements by mouth every day for up to 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate in Hemoglobin (HGB)
Time Frame: 3 months
|
The primary endpoint is response (CR rate) in HGB within 3 months.
Participant considered as to have a complete response (CR) if his/her HGB level increases > 2 g/dL from baseline during 3 months following initiation of the study drug, and/or transfusion-dependent patient is transfusion free.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Neoplasms, Connective Tissue
- Neoplasms
- Anemia, Iron-Deficiency
- Gastrointestinal Stromal Tumors
- Anemia
Other Study ID Numbers
- 2015-0588
- NCI-2016-01925 (Registry Identifier: NCI CTRP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasms of Mesothelial and Soft Tissue
-
Fudan UniversityUnknownLocal Recurrence of Malignant Tumor of Soft TissueChina
-
Masaryk Memorial Cancer InstituteUnknownMalignant Tumor of Soft Tissue of Head, Face and NeckCzechia
-
Istituto Clinico HumanitasActive, not recruitingMetastasis From Malignant Tumor of Soft TissuesItaly
-
M.D. Anderson Cancer CenterEisai Inc.WithdrawnAdvanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
-
M.D. Anderson Cancer CenterWithdrawnMalignant Neoplasms of Mesothelial and Soft Tissue | Rhabdomyosarcoma, Pelvic | Rhabdomyosarcoma, Abdominal
-
Philips HealthcarePhilips Electronics Nederland B.V. acting through Philips CTO organizationCompletedMalignant Lymphoma of Lymph Nodes of Inguinal Region | Malignant Lymphoma of Lymph Nodes of Axillary | Malignant Lymphoma of Lymph Nodes of the Cervix | Carcinoma of Parotid Gland | Colon Rectal Cancer Tubulovillous Adenocarcinoma | Tumor of Soft Tissue of Head, Face and NeckNetherlands
-
University of MiamiCompletedSarcoma | Childhood Malignant Fibrous Histiocytoma of BoneUnited States
-
European Paediatric Soft Tissue Sarcoma Study GroupChildren's Cancer and Leukaemia Group; Dutch Childhood Oncology Group; Italian... and other collaboratorsUnknownSarcoma | Childhood Malignant Fibrous Histiocytoma of BoneIreland, United Kingdom, Spain, Austria, Belgium, Denmark, France, Sweden, Switzerland
-
Columbia UniversityCelgene Corporation; Schering-PloughUnknownSoft Tissue Sarcoma | MesotheliomaUnited States
-
Alpha Tau Medical LTD.CompletedMalignant Skin Tumor | Soft Tissue Tumor, MalignantUnited States
Clinical Trials on Ferric Carboxymaltose
-
Sichuan Huiyu Pharmaceutical Co., LtdThe First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaboratorsCompletedBioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency AnaemiaIron Deficiency | AnaemiaChina
-
Hasselt UniversityZiekenhuis Oost-LimburgCompleted
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
St Joseph University, Beirut, LebanonSaint-Joseph University; Vifor PharmaCompletedAnemia, Iron DeficiencyLebanon
-
Istanbul UniversityRecruitingAnemia | Hip Fractures | Complication,PostoperativeTurkey
-
Vifor PharmaTerminatedIron-Deficiency AnemiaFrance, Greece
-
American Regent, Inc.Completed
-
University of ZurichTerminated